Cargando…
PET and CSF amyloid-β status are differently predicted by patient features: information from discordant cases
BACKGROUND: Amyloid-β PET and CSF Aβ(42) yield discordant results in 10–20% of memory clinic patients, possibly providing unique information. Although the predictive power of demographic, clinical, genetic, and imaging features for amyloid positivity has previously been investigated, it is unknown w...
Autores principales: | Reimand, Juhan, de Wilde, Arno, Teunissen, Charlotte E., Zwan, Marissa, Windhorst, Albert D., Boellaard, Ronald, Barkhof, Frederik, van der Flier, Wiesje M., Scheltens, Philip, van Berckel, Bart N. M., Ossenkoppele, Rik, Bouwman, Femke |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6898919/ https://www.ncbi.nlm.nih.gov/pubmed/31810489 http://dx.doi.org/10.1186/s13195-019-0561-5 |
Ejemplares similares
-
Discordant amyloid-β PET and CSF biomarkers and its clinical consequences
por: de Wilde, Arno, et al.
Publicado: (2019) -
Why Is Amyloid-β PET Requested After Performing CSF Biomarkers?
por: Reimand, Juhan, et al.
Publicado: (2020) -
Amyloid‐β PET and CSF in an autopsy‐confirmed cohort
por: Reimand, Juhan, et al.
Publicado: (2020) -
Combination of plasma amyloid beta((1-42/1-40)) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology
por: Verberk, Inge M. W., et al.
Publicado: (2020) -
Clinical outcomes up to 9 years after [(18)F]flutemetamol amyloid-PET in a symptomatic memory clinic population
por: Collij, Lyduine E., et al.
Publicado: (2023)